Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy

Cancer Biology and Therapy

Volumn 12, Issue 3, 2011, Pages 165-168

  Sonnenblick, Amir ^a   Kadouri, Luna ^a   Appelbaum, Liat ^a   Peretz, Tamar ^a   Sagi, Michal ^a   Goldberg, Yael ^a   Hubert, Ayala ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

BRCA; Cisplatin; DNA damage; Pancreatic adenocarcinoma

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; GEMCITABINE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GENETIC ANALYSIS; HUMAN; LEUKEMIA REMISSION; MALE; PANCREAS ADENOCARCINOMA; POINT MUTATION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA2 PROTEIN; CISPLATIN; DEOXYCYTIDINE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 79961228580     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.3.16292     Document Type: Article

References (20)

1. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with Gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. (Pubitemid 27251144)
2. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between Cisplatin and Gemcitabine in vitro. Clin Cancer Res 1996; 2:521-30. (Pubitemid 26099172)
3. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with Cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94:902-10; DOI: 10.1002/cncr.10323.abs.
4. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B, et al. Randomized phase III trial of Gemcitabine plus Cisplatin compared with single-agent Gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010; 28:1645-51; DOI: 10.1200/JCO.2009.25.4433.
5. Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1997; 1:47-51. (Pubitemid 127526937)
6. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95:214-21; DOI: 10.1093/jnci/95.3.214.
7. Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009; 27:433-8; DOI: 10.1200/ JCO.2008.18.5546.
8. Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst 1999; 91:1310-6.
9. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001; 27:247-54; DOI: 10.1038/85798.
10. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7:263-72; DOI: 10.1016/S1097- 2765(01)00174-5.
11. Thompson LH. Unraveling the Fanconi anemia-DNA repair connection. Nat Genet 2005; 37:921-2; DOI: 10.1038/ng0905-921.
12. Wang X, Andreassen PR, D'Andrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004; 24:5850-62; DOI: 10.1128/MCB.24.13.5850-62.2004.
13. Yang H, Li Q, Fan J, Holloman WK, Pavletich NP. The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction. Nature 2005; 433:653-7; DOI: 10.1038/nature03234.
14. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 2000; 10:144-50; DOI: 10.1016/S0959-437X(00)00069-1.
15. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283:2260-5; DOI: 10.1001/jama.283.17.2260.
16. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in Cisplatin-sensitive ovarian tumors. Nat Med 2003; 9:568-74; DOI: 10.1038/nm852.
17. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with Cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009; 115:359-63; DOI: 10.1007/s10549-008- 0128-9.
18. Moiseyenko VM, Protsenko SA, Brezhnev NV, Maximov SY, Gershveld ED, Hudyakova MA, et al. High sensitivity of BRCA1-associated tumors to Cisplatin monotherapy: report of two cases. Cancer Genet Cytogenet 2010; 197:91-4; DOI: 10.1016/j.cancergencyto.2009.10.003.
19. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of Cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451:1116-20; DOI: 10.1038/ nature06633.
20. Powell SN, Kachnic LA. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 2008; 8:448-60. (Pubitemid 351761429)